7 results
Primary ObjectiveThe primary objective of this study is to evaluate glycogen clearance in muscle tissue samples collected pre and post alglucosidase alfa treatment in patients with late-onset Pompe disease.Secondary ObjectivesThe secondary…
Primary objective: To evaluate the non-inferiority of QVA149 110/50 µg qd as compared to concurrentadministration of QAB149 150 µg qd plus NVA237 50 µg qd in terms of its effect on trough FEV1 (mean of 23 h 15 min and 23 h 45 min post-dose)…
The aim of this study is to prove the efficacy of 3 times daily 1 mg glycopyrronium bromide versus placebo in patients with PD with hypersalivation. Furthermore, the safety of glycopyrronium bromide used in the mentioned dosage will be further…
The primary objective is to investigate the safety and tolerability of inhalation of glycopyrronium inhalation powder using different dosing regimens. The second objectives are to determine the decrease in drooling by using different dosing regimens…
The overall objective of this study is to evaluate the efficacy and safety of neoGAA in treatment-naïve patients with LOPD as compared to alglucosidase alfa, when this is administered biweekly for a period of 49 weeks. Also, there is an open-label…
To determine if inhibition with GPB can provide a significant reduction in the accumulation of systemically administered Ga-PSMA in salivary glands on PET/CT, with the aim to determine if GPB can prevent toxicity from Lu-PSMA or other…
Primary: to compare improvement on the Health Assessment Questionnaire (HAQ) between HandScan guided tight control and treat-to-target treatment and the conventional ACR/EULAR remission guided tight control and treat-to-target treatment of RA after…